State Street Corp Buys 1,182,181 Shares of Replimune Group, Inc. (NASDAQ:REPL)

State Street Corp boosted its position in Replimune Group, Inc. (NASDAQ:REPL) by 102.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,340,042 shares of the company’s stock after purchasing an additional 1,182,181 shares during the quarter. State Street Corp owned approximately 3.42% of Replimune Group worth $25,647,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Parkman Healthcare Partners LLC raised its stake in shares of Replimune Group by 45.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after acquiring an additional 238,747 shares in the last quarter. Arizona PSPRS Trust purchased a new position in Replimune Group in the third quarter worth $834,000. Baker BROS. Advisors LP increased its position in shares of Replimune Group by 10.0% during the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Replimune Group during the 3rd quarter valued at $133,000. Finally, Braidwell LP boosted its position in shares of Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after purchasing an additional 2,057,460 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This represents a 4.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on REPL shares. Roth Mkm began coverage on Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 24th. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Jefferies Financial Group lifted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a research report on Friday, November 22nd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Replimune Group has a consensus rating of “Buy” and an average target price of $17.29.

Replimune Group Stock Up 4.0 %

NASDAQ:REPL opened at $12.49 on Monday. The firm has a market capitalization of $854.53 million, a P/E ratio of -4.10 and a beta of 1.26. The company’s fifty day moving average price is $12.25 and its 200-day moving average price is $10.77. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. As a group, equities research analysts anticipate that Replimune Group, Inc. will post -2.91 EPS for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.